|
|
|
|
|
|
|
09.12.25 - 11:31
|
Bear of the Day: AptarGroup (ATR) (Zacks)
|
|
|
AptarGroup's (ATR) stock has been falling due to a mix of legal costs, inventory challenges, analyst downgrades, and weaker demand in certain healthcare markets....
|
|
|
02.12.25 - 20:21
|
Aptar Strengthens Latin America Footprint With Sommaplast Buy (Benzinga)
|
|
|
AptarGroup acquired Sommaplast, a specialized provider of oral dosing pharma packaging solutions in Brazil for $30-$35 million.
Latest Ratings for ATR
DateFirmActionFromTo Jan 2022Morgan StanleyMaintainsEqual-Weight Dec 2021Wells FargoMaintainsOverweight Dec 2021Deutsche BankMaintainsBuy
View More Analyst Ratings for ATR
View the Latest Analyst Ratings
read more...
|
|
|
01.12.25 - 23:03
|
Aptar Acquires Sommaplast, a Specialized Provider of Oral Dosing Pharma Packaging Solutions (Business Wire)
|
|
|
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has acquired Sommaplast, a specialized provider of oral dosing pharma packaging solutions, such as closures, droppers, dispensers and dosing cups, based in Brazil.
“Aptar has manufactured in Brazil for 25 years and this acquisition is expected to further reinforce our footprint in the region. It also helps position us to capitalize on Brazil's fast-growing oral dosing, over-the-counter and nutraceutical markets. This growth is driven by an expanding population, rising middle class and aging demographic,” explained Gael Touya, President, Aptar Pharma.
Sommaplast was founded over 20 years ago and operates from a facility in Sao Paulo, Brazil with a team of over 400 employees. Today, Sommaplast is recognized for its strong team, deep customer relationships and high level of dosing know-how. With this acquisition, Aptar is ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.10.25 - 22:06
|
Aptar Reports Third Quarter 2025 Results (Business Wire)
|
|
|
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, today reported the following third quarter results for the period ended September 30, 2025, as compared to the corresponding period of the last fiscal year.
Third Quarter 2025 Highlights
(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)
Reported sales increased 6% and core sales increased 1%
Strong product volume growth in Closures and Pharma, especially in injectables
Reported net income increased 28% to $128 million and reported earnings per share increased 30% to $1.92
Adjusted earnings per share, which also excludes non-ordinary-course litigation costs (see Non-GAAP section for full definition), increased 4% to $1.62
Adjusted EBITDA, which also excludes non-ordinary-course litigation costs, increased 7% to $223 million
Adjusted EBITDA margin was 23.2% compared to 22...
|
|
|
|
|
|
|
|
|
|
|
21.10.25 - 23:54
|
XFRA: DIVIDEND/INTEREST INFORMATION - 23.10.2025 - US0383361039 (XETRA)
|
|
|
Das Instrument AGT US0383361039 APTARGRP INC. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 22.10.2025 und ex Dividende/Zinsen am 23.10.2025
The instrument AGT US0383361039 APTARGRP INC. DL-,01 EQUITY has its pre-dividend/interest day on 22.10.2025 and its ex-dividend/interest day on 23.10.2025...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
